Answers are grounded in this paper and cite their sources.
Introduction Sodium–glucose cotransporter 2 (SGLT2) inhibitors lower glucose through glucosuria, but it remains unclear whether treatment initiation is accompanied by a compensatory increase in energy intake or whether individual glycemic improvement is associated with recorded intake or craving. We examined 12-week changes and associations among these measures. Methods This single-arm, open-label interventional study assessed 44 adults with type 2 diabetes using continuous glucose monitoring (CGM), food diaries, the General Food Cravings Questionnaire–Trait, and appetite visual analogue scales (VAS). Glycemic improvement was assessed using HbA1c reduction and CGM-derived metrics. Changes in recorded energy intake, meal frequency, and appetite (the protocol-specified primary outcome) were compared across tertiles of HbA1c change using tests selected post hoc . In exploratory analyses, each glycemic outcome was regressed on the Week-12 craving or dietary measure, adjusting for baseline glycemia and the corresponding baseline measure, with Benjamini–Hochberg control (Q values). Results Over 12 weeks, HbA1c decreased by 0.90 percentage points (9.8 mmol/mol; 95% CI, −1.10 to −0.69), time in range increased by 22.1 percentage points, and body weight decreased by 2.14 kg (all P < 0.001). Recorded energy intake showed no statistically detectable increase (−98 kcal/day; 95% CI, −212 to +15; P = 0.088), while recorded carbohydrate and total sugar intakes decreased. None of the eight appetite VAS domains changed detectably. Across HbA1c-change tertiles, no statistically detectable difference was observed in changes in energy intake (P = 0.694), in the proportion of participants who stopped reporting three meals per day (P = 0.594), or in appetite after false-discovery-rate correction (all Q ≥ 0.20). After adjustment for baseline values, a lower Week-12 Loss of Control score was associated with greater HbA1c reduction (standardized β = −0.50; 95% CI, −0.85 to −0.14; Q = 0.029); recorded energy, carbohydrate, and total sugar intake were not. Conclusion Glycemia improved after SGLT2 inhibitor initiation without a statistically detectable increase in recorded energy intake or rated appetite over 12 weeks, although compensatory intake cannot be excluded. Glycemic improvement was not associated with recorded dietary measures, whereas Loss of Control was the most consistent exploratory craving correlate. Craving warrants evaluation alongside dietary intake in controlled studies. Clinical trial registration https://cris.nih.go.kr , identifier KCT0007619.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: